Pindolol augmentation of antidepressant treatment: Recent contributions from brain imaging studies

Biological Psychiatry

Volumn 48, Issue 8, 2000, Pages 844-853

  Martinez, Diana ^a,b   Broft, Allegra ^a   Laruelle, Marc ^a  

^a New York State Psychiatric Institute ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

11C WAY 100635; Major depression; PET; Pindolol; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; CARBON 11; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PAROXETINE; PINDOLOL; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

BRAIN TOMOGRAPHY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DORSAL RAPHE NUCLEUS; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; DRUG SELECTIVITY; HUMAN; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; POSTSYNAPTIC INHIBITION; PRIORITY JOURNAL; RECEPTOR OCCUPANCY;

ANIMALS; BRAIN; CEREBROVASCULAR CIRCULATION; CLINICAL TRIALS; DEPRESSIVE DISORDER, MAJOR; DRUG SYNERGISM; FLUOXETINE; HUMANS; PAROXETINE; PINDOLOL; RATS; SEROTONIN UPTAKE INHIBITORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034667307     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)00993-8     Document Type: Conference Paper

References (90)

1. Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography
2. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors
3. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists
4. (-)-Pindolol and (±)-tertatolol affect rat hippocampal 5-HT levels through mechanisms involving not only 5-HT1A, but also 5-HT1B receptors
5. Fast onset: An open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy
6. The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial
7. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: A double-blind, placebo-controlled trial
8. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression
9. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response
10. Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat
11. Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors
12. Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: Electrophysiological studies in the rat brain
13. Differential effect of gepirone on presynaptic and postsynaptic serotonin receptors: Single-cell recording studies
14. Current advances and trends in the treatment of depression
15. Differential properties of pre- and postsynaptic 5-hydroxytryptamine 1A receptors in the dorsal raphe and hippocampus: II. Effect of pertussis and cholera toxins
16. Reseau de Recherche et d'Experimentation Psychopharmacologique
17. 5-Hydroxytryptamine release in dorsal hippocampus of freely moving rats: Modulation by pindolol
18. Affinity of beta-adrenergic ligands for pre- and postsynaptic 5-HT1A recetors in human brain
19. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: Electrophysiological studies in the rat brain
20. Lack of 5-hydroxytryptamine 1A-mediated inhibition of adenylyl cyclase in dorsal raphe of male and female rats
21. Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5-HT1A autoreceptor in vivo
22. Antagonist properties of (-)-pindolol and WAY 100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain
23. The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: The mechanism of action of (±)pindolol
24. Does pindolol induce a rapid improvement in depressed patients resistant to serotonin reuptake inhibitors?
25. Enhancement of fluoxetine-dependent increase of extracellular serotonin (5-HT) levels by (-)-pindolol, an antagonist at 5-HT1A receptors
26. Physical evidence of the coupling of solubilized 5-HT1A binding sites with G regulatory proteins
27. Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man
28. WAY100135: A novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors
29. Pindolol increases extracellular 5-HT while inhibiting serotonergic neuronal activity
30. Pindolol, a putative 5-hydroxytryptamine(1A) antagonist, does not reverse the inhibition of serotonergic neuronal activity induced by fluoxetine in awake cats: Comparison to WAY-100635
31. Pindolol suppresses serotonergic neuronal activity and does not block the inhibition of serotonergic neurons produced by 8-hydroxy-2-(di-n-propylamino)tetralin in awake cats
32. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635
33. Effects of (-)-tertatolol, (-)-penbutolol and (±)-pindolol in combination with paroxetine on presynaptic 5-HT function: An in vivo microdialysis and electrophysiological study
34. Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: Comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors
35. Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine - I. Effects of acute and long-term administration of tandospirone on serotonin neurotransmission
36. The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes
37. Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET
38. Chronic electroconvulsive shock and 5-HT autoreceptor activity in rat brain: An in vivo microdialysis study
39. Modulation of the firing activity of rat serotonin and noradrenaline neurons by (±)pindolol
40. Characterization of 5-hydroxytryptamine1A properties of flesinoxan: In vivo electrophysiology and hypothermia study
41. Differentiation of pre- and post-synaptic high affinity serotonin receptor binding sites using physico-chemical parameters and modifying agents
42. A rating scale for depression
43. Modulation of 5-hydroxytryptamine1A receptor density by nonhydrolyzable GTP analogues
44. Pindolol occupancy of 5HT1A receptors measured in vivo using small animal positron emission tomography with carbon-11 labelled WAY 100635
45. (-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine
46. Further evidence for the importance of 5-HT1A autoreceptors in the action of selective serotonin reuptake inhibitors
47. 5-HT1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI)
48. Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors?
49. The 5-HT 1A receptor agonist, 8-OH-DPAT, preferentially activates cell body 5-HT autoreceptors in rat brain in vivo
50. Mixed agonist/antagonist properties of NAN-190 at 5-HT1A receptors: Behavioural and in vivo brain microdialysis studies
51. In vivo microdialysis evidence for central serotonin1A and serotonin1B autoreceptor blocking properties of the beta adrenoceptor antagonist (-)penbutolol
52. 5-HT receptors: Subtypes and second messengers
53. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex
54. [3H]8-OH-DPAT labels a 5-HT site coupled to inhibition of phosphoinositide hydrolysis in the dorsal raphe
55. Central pre- and postsynaptic 5-HT1A receptors in rats treated chronically with a novel antidepressant, cericlamine
56. Analysis of emission tomographic scan data: Limitations imposed by resolution and background
57. Quantitative autoradiographic characterisation of the binding of [3H]WAY-100635, a selective 5-HT1A receptor antagonist
58. Characterisation of the binding of [3H]WAY-100635, a novel 5-hydroxytryptamine1A receptor antagonist, to rat brain
59. Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine
60. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: Implications for the neurobiology of depression
61. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance
62. Effects of imipramine on raphe nuclei and prefrontal cortex extracellular serotonin levels in the rat
63. Antidepressant-like action of 8-OH-DPAT, a 5-HT1A agonist, in the learned helplessness paradigm: Evidence for a postsynaptic mechanism
64. Antidepressant-like effects of buspirone mediated by the 5-HT1A post-synaptic receptors in the learned helplessness paradigm
65. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: A dose-occupancy study with [(11)C]WAY 100635 and positron emission tomography in humans
66. Serotonin (5-HT) release in the dorsal raphe and ventral hippocampus: Raphe control of somatodendritic and terminal 5-HT release
67. 5-Hydroxytryptamine(1A) receptor-stimulated [(35)S]GTPgammaS binding in rat brain: Absence of regional differences in coupling efficiency
68. Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: A pharmacological characterization of the actions of novel agonists and antagonists
69. Further evidence for differential affinity states of the serotonin1A receptor in rat hippocampus
70. Pindolol augmentation of treatment-resistant depressed patients
71. Heterogeneity of cortical and hippocampal 5-HT1A receptors: A reappraisal of homogenate binding with 8-[3H]hydroxydipropylaminotetralin
72. Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: Definition of its binding profile using agonists, antagonists and inverse agonists
73. Validation and reproducibility of measurement of 5-HT1A receptors parameters with [carbonyl-11C]WAY-100635 in humans: Comparison of arterial and reference tissue input functions
74. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment
75. Augmentation of fluoxetine antidepressant action by pindolol: Analysis of clinical pharmacokinetic, and methodological factors
76. Grup de Recerca en Trastorns Afectius
77. First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635
78. Beta-blocker binding to human 5HT1A receptors in vivo and in vitro: Implications for antidepressant therapy
79. Pharmacological and physicochemical properties of pre-versus postsynaptic 5-hydroxytryptamine1A receptor binding sites in the rat brain: A quantitative autoradiographic study
80. Displacement of the binding of 5-HT(1A) receptor ligands to pre- and postsynaptic receptors by (-)pindolol. A comparative study in rodent, primate and human brain
81. Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: In vivo microdialysis and electrophysiological studies in the rat brain
82. Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: Biochemical and electrophysiological studies
83. Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis
84. Application of brain microdialysis to study the pharmacology of the 5-HT1A autoreceptor
85. Effect of acute and repeated administration of 5-HT1A receptor agonists on 5-HT release in rat brain in vivo
86. Anxiolytic 5-hydroxytryptamine1A agonists suppress firing activity of dorsal hippocampus CA1 pyramidal neurons through a postsynaptic mechanism: Single-unit study in unanesthetized, unrestrained rats
87. Paroxetine and pindolol: A randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency
88. Pindolol accelerates the therapeutic action of selective serotonin reuptake inhibitors (SSRI) in depression
89. How long should pindolol be associated with paroxetine to improve the antidepressant response?
90. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study